Hundreds of compounds have been identified using ethnobotany, investigating plants used by indigenous peoples for possible medical applications. Some important phytochemicals, including curcumin, epigallocatechin gallate, genistein and resveratrol are pan-assay interference compounds, meaning that "in vitro" studies of their activity often provide unreliable data. As a result, phytochemicals have frequently proven unsuitable as lead compounds in drug discovery. In the United States over the period 1999 to 2012, despite several hundred applications for new drug status, only two botanical drug candidates had sufficient evidence of medicinal value to be approved by the Food and Drug Administration.